Early intervention in psoriasis and immune-mediated inflammatory diseases : A hypothesis paper
Girolomoni, Giampiero (University of Verona)
Griffiths, Christopher Ernest Maitland (University of Manchester)
Krueger, James (Rockefeller University)
Nestle, Frank O. (King's College London)
Nicolas, Jean François (University of Lyon)
Prinz, Jörg Christoph (University of Munich)
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau)
Ståhle, Mona (Karolinska Institutet (Estocolm, Suècia))
Van De Kerkhof, Peter C.M. (Nijmegen Medical Centre)
Allez, Matthieu (Universite Denis Diderot Paris)
Emery, Paul (Leeds Teaching Hospitals (Regne Unit))
Paul, Caul (Paul Sabatier University (Tolosa))
Universitat Autònoma de Barcelona. Departament de Medicina

Date:	2015
Abstract:	Psoriasis is an immune-mediated inflammatory disease (IMID) which may have a major impact on a patient's life, especially when the disease is moderate to severe. There is evidence that treatment of psoriasis during the first years is conservative and frequently based on topical agents which rarely clear lesions. Treatment with systemic agents including biologics is often undertaken only when topical agents have proved unsuitable, even in patients with moderate to severe disease. However, there is evidence that in other IMIDs (rheumatoid arthritis and Crohn's disease), targeted systemic treatment given early in the treatment pathway may improve long-term patient outcomes. We hypothesize that a patient-centered therapeutic approach, undertaken early in the psoriasis treatment pathway ("early intervention") with the goal of complete clearance, may improve control of cutaneous symptoms and may also modify disease course and burden. Critical points to address when designing an early intervention study would include: the definition of psoriasis disease activity; patient selection; intervention selection; and dosing strategies.
Note:	The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article. Funding sources: Development of this article was supported by Janssen Pharmaceutica NV.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article de revisió ; recerca ; Versió publicada
Subject:	Comorbidities ; Early intervention ; Management ; Pathophysiology ; Psoriasis
Published in:	Journal of Dermatological Treatment, Vol. 26 Núm. 2 (january 2015) , p. 103-112, ISSN 1471-1753

DOI: 10.3109/09546634.2014.880396
PMID: 24547907

11 p, 519.7 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles